DNA Computing Chip BioLogic Completes First Commercial Prototype: Molecular-Scale Parallel Computing Exits the Lab
MIT spinoff Catalog Technologies released the BioLogic DNA computing chip commercial prototype, capable of performing over 1 billion parallel logic operations in a single reaction, with initial applications targeting drug molecule screening and cryptography.
Full Article
MIT spinoff Catalog Technologies released the first commercial prototype of its BioLogic DNA computing chip on May 12. The chip leverages DNA molecule self-assembly properties to achieve massively parallel logic operations, capable of performing over 1 billion basic logic operations in a single biochemical reaction.
BioLogic's core principle encodes computational problems as DNA sequences, using the specificity of DNA base pairing to implement logic gate operations. Unlike traditional electronic chips' serial or limited parallel computation, DNA computing's parallelism is determined by molecular quantity, theoretically reaching astronomical levels.
Catalog Technologies CEO Hyunjun Park said BioLogic's initial commercial scenarios target two areas: large-scale combinatorial optimization in drug molecule screening and lattice-based problem solving in post-quantum cryptography. "Traditional electronic computers might need years to solve these problems, but BioLogic can complete them in hours."
The company has entered partnership agreements with Pfizer and Novartis to trial BioLogic in their drug discovery pipelines. However, DNA computing's read/write speed, error rate, and cost remain major barriers to industrialization.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.